Cargando…
A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2
Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703546/ https://www.ncbi.nlm.nih.gov/pubmed/33290969 http://dx.doi.org/10.1016/j.intimp.2020.107232 |
_version_ | 1783616660312162304 |
---|---|
author | Kivrak, Arif Ulaş, Berdan Kivrak, Hilal |
author_facet | Kivrak, Arif Ulaş, Berdan Kivrak, Hilal |
author_sort | Kivrak, Arif |
collection | PubMed |
description | Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it. Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients. They prevent cytokine storm that is the main reason of deaths related to SARS-CoV-2. In addition, anti-inflammatory agents have critical roles to inhibit the lung injury and multisystem organ dysfunction. The combination with anti-viral drugs with other drugs displays high synergistic effects. In the present study, the drugs used for Covid-19 are analyzed and compare the efficiency for the Covid-19 patients from the different continents including USA, South Korea, Italy, Spain, Germany, Russia, Brazil, Turkey, and China. Nowadays, all countries tried to find vaccine and new drug candidates for SARS-CoV-2, but anti-viral drugs may be the best candidates for the treatment of Covid-19 before finding novel anti-Covid drug. |
format | Online Article Text |
id | pubmed-7703546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77035462020-12-01 A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 Kivrak, Arif Ulaş, Berdan Kivrak, Hilal Int Immunopharmacol Review Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it. Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients. They prevent cytokine storm that is the main reason of deaths related to SARS-CoV-2. In addition, anti-inflammatory agents have critical roles to inhibit the lung injury and multisystem organ dysfunction. The combination with anti-viral drugs with other drugs displays high synergistic effects. In the present study, the drugs used for Covid-19 are analyzed and compare the efficiency for the Covid-19 patients from the different continents including USA, South Korea, Italy, Spain, Germany, Russia, Brazil, Turkey, and China. Nowadays, all countries tried to find vaccine and new drug candidates for SARS-CoV-2, but anti-viral drugs may be the best candidates for the treatment of Covid-19 before finding novel anti-Covid drug. Elsevier B.V. 2021-01 2020-11-30 /pmc/articles/PMC7703546/ /pubmed/33290969 http://dx.doi.org/10.1016/j.intimp.2020.107232 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Kivrak, Arif Ulaş, Berdan Kivrak, Hilal A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 |
title | A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 |
title_full | A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 |
title_fullStr | A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 |
title_full_unstemmed | A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 |
title_short | A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2 |
title_sort | comparative analysis for anti-viral drugs: their efficiency against sars-cov-2 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703546/ https://www.ncbi.nlm.nih.gov/pubmed/33290969 http://dx.doi.org/10.1016/j.intimp.2020.107232 |
work_keys_str_mv | AT kivrakarif acomparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2 AT ulasberdan acomparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2 AT kivrakhilal acomparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2 AT kivrakarif comparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2 AT ulasberdan comparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2 AT kivrakhilal comparativeanalysisforantiviraldrugstheirefficiencyagainstsarscov2 |